Concepedia

Everolimus-based Regimens

Everolimus-Based Regimens is a pharmacological intervention strategy in transplant immunosuppression that incorporates everolimus, a mammalian target of rapamycin (mTOR) inhibitor, as a core agent to prevent allograft rejection while minimizing calcineurin inhibitor exposure.

688

Publications

47.9K

Citations

5K

Authors

1.6K

Institutions

Publications per year

2017–2026

184

Parents

Publications

688

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

Robert J. Motzer, Bernard Escudier, Saby George et al. · New England Journal of Medicine · 2015 · 5.9K citations · Full text

, , +17

Phase 3 trial of everolimus for metastatic renal cell carcinoma

Robert J. Motzer, Bernard Escudier, Stéphane Oudard et al. · Cancer · 2010 · 1.1K citations

, , +17

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

Marianne Pavel, John D. Hainsworth, Éric Baudin et al. · The Lancet · 2011 · 1.1K citations

, , +16

Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis

Darcy A. Krueger, Marguerite M. Caré, Katherine Holland et al. · New England Journal of Medicine · 2010 · 1K citations · Full text

, , +13

Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial

Robert J. Motzer, Thomas E. Hutson, Hilary Glen et al. · The Lancet Oncology · 2015 · 943 citations · Full text

, , +14

1–5 of 688

Authors

5K

  1. RJ
    Robert J. Motzer

    Memorial Sloan Kettering Cancer Center, United States

    20 publications · 10.1K citations

    18

    h-index

  2. HT
    Hélio Tedesco‐Silva

    Hospital do Rim e Hipertensão, Brazil

    18 publications · 1.6K citations

    17

    h-index

  3. JP
    Julio Pascual

    Hospital Del Mar, Spain

    15 publications · 1.2K citations

    15

    h-index

  4. BE
    Bernard Escudier

    Institut Gustave Roussy, France

    14 publications · 8.4K citations

    14

    h-index

  5. CS
    Claudia Sommerer

    Heidelberg University, Germany

    20 publications · 1.5K citations

    14

    h-index

1–5 of 5K

Institutions

1.6K

  1. Novartis (Switzerland)

    Basel, Switzerland

    51 h-index

    244 publications

    29.8K citations

  2. Novartis (United States)

    New York, United States

    35 h-index

    113 publications

    16.4K citations

  3. Medizinische Hochschule Hannover

    Hanover, Germany

    27 h-index

    82 publications

    5.6K citations

  4. Dana-Farber Cancer Institute

    Boston, United States

    26 h-index

    154 publications

    14.6K citations

  5. Charité - Universitätsmedizin Berlin

    Berlin, Germany

    26 h-index

    97 publications

    6.5K citations

  6. Institut Gustave Roussy

    Villejuif, France

    26 h-index

    84 publications

    19K citations

  7. The University of Texas MD Anderson Cancer Center

    Houston, United States

    25 h-index

    165 publications

    13.6K citations

  8. Memorial Sloan Kettering Cancer Center

    New York, United States

    24 h-index

    72 publications

    11.8K citations

1–8 of 1.6K

Venues

  1. Transplantation

    68 publications · 5.6K citations

    40

    h-index

  2. American Journal of Transplantation

    46 publications · 4.7K citations

    37

    h-index

  3. Transplantation Proceedings

    63 publications · 1.6K citations

    26

    h-index

  4. Journal of Clinical Oncology

    41 publications · 3.2K citations

    24

    h-index

  5. Annals of Oncology

    23 publications · 1.6K citations

    19

    h-index

1–5